Sobi to present clinical data on Gamifant® at Histiocyte Society 2026 in Rotterdam
STOCKHOLM, Sept. 24, 2026 /PRNewswire/ -- Sobi® (STO: SOBI) today announced that new clinical data on Gamifant® (emapalumab) in primary haemophagocytic lymphohistiocytosis (HLH) will be presented at the 2026 Annual Meeting of the Histiocyte Society (HS2026), taking place 26-29 September in Rotterdam, the Netherlands.
The accepted abstracts include a new pooled analysis of pre- and post-transplant survival outcomes across three prospective trials, two encore presentations of analyses in primary HLH, and data from a post-authorisation study in treatment-experienced Chinese patients.
"Sobi is continuing to build the evidence on treatment and transplant outcomes in primary HLH to help people with this rare, life-threatening hyperinflammatory disease. The new pooled-analysis has been selected as one of the ten highest-scoring poster abstracts and nominated for the Robert J. Arceci Prize for Best Poster, which is highly encouraging as it recognises our scientific impact," said Lydia Abad-Franch, MD, Head of R&D and Medical Affairs and Chief Medical Officer at Sobi.
Poster presentations | ||
Gamifant® (emapalumab) | Pre- and Post-Transplant Survival with Emapalumab in Primary HLH: Pooled Analysis of Prospective Trials NI-0501-04, NI-0501-05 and NI-0501-09 | Poster Pitch Session, September 29 15:45-17:00 local time |
Emapalumab Induces Rapid, Durable Responses and Bridging to Curative HSCT in Patients with pHLH | Poster session, September 29 15:45-17:00 local time | |
Emapalumab is Associated with Rapid and Sustained Benefits in Primary HLH Subgroups regardless of Previous Treatment or Central Nervous System Involvement | Poster session, September 29 15:45-17:00 local time | |
Emapalumab in Treatment-Experienced Primary HLH: Safety, Efficacy, and Transplant Outcomes from the Open-Label, Single-Arm Post-Authorization Study Sobi.EMAPALUMAB-104 in Chinese Patients | Poster session, September 29 15:45-17:00 local time | |
About Gamifant® (emapalumab)
Gamifant is the only approved anti-interferon gamma (IFNy) monoclonal antibody. Gamifant works by binding to and neutralising interferon gamma (IFNy). When interferon gamma (IFNy) is secreted in an uncontrolled manner, hyperinflammation occurs within the body. Gamifant is indicated for administration through intravenous infusion over one hour.
Gamifant is approved in the US for the treatment of adult and paediatric patients with primary haemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent or progressive disease or intolerance with conventional HLH therapy. Gamifant is also approved in the US for the treatment of adult and paediatric patients with haemophagocytic lymphohistiocytosis (HLH)/macrophage activation syndrome (MAS) in known or suspected Still's disease with an inadequate response or intolerance to glucocorticoids, or with recurrent MAS.
Sobi®
Sobi is a global biopharma company unlocking the potential of breakthrough innovations, transforming everyday life for people living with rare diseases. Sobi has approximately 2000 employees across Europe, North America, the Middle East, Asia and Australia. In 2025, revenue amounted to SEK 28 billion. Sobi's share (STO:SOBI) is listed on Nasdaq Stockholm. More about Sobi at sobi.com and LinkedIn.
For details on how to contact the Sobi Investor Relations Team, please click here. For Sobi Media contacts, click here.
CONTACT: Visiting address
Norra Stationsgatan 93A, Stockholm
+46 8 697 20 00
[email protected]
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
Sobi to present clinical data on Gamifant® at Histiocyte Society 2026 in Rotterdam |
Share this article